Revium Rx, an Israeli biotech company, has announced the completion of its acquisition of LipoVation, a development-stage pharma company also based in Israel. The firm will now become a wholly owned subsidiary of Revium Rx, in accordance with the company’s commitment to drug delivery innovation.

This acquisition comes as part of Revium Rx’s strategic refocus on nanoparticle-based therapeutics, with LipoVation specialising in lipid-based nano- and micro-particle based therapeutic drugs.